All In Biotech

Free tool

FAERS Monitor: Arazlo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211882 or its brand name (Arazlo, Tazarotene). Reports on generic versions are filed under their own applications.

Reports

350

Serious

137

39% of reports

Hospitalization

56

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective55
  • off label use34
  • headache21
  • diarrhoea17
  • nausea16
  • product use in unapproved indication16
  • dry skin15
  • psoriasis15
  • application site discolouration14
  • pain14
  • skin exfoliation14
  • treatment failure14
  • erythema12
  • pruritus12
  • acne11

Reports by year received

View as table
YearReports
20042
20061
20073
20083
20092
20103
20114
20122
20131
20142
20154
201613
20173
201811
201922
202013
202120
202240
202372
202448
202535
202646

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,809 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site discolourationSignal14207.8124.32,669
treatment failureSignal1410.26.1107
skin exfoliationSignal1410.06.0105
acneSignal118.74.968
psoriasisSignal156.94.270
dry skinSignal156.84.168
product use in unapproved indicationSignal163.92.432
erythemaSignal123.52.019
drug ineffectiveSignal552.52.052
off label useSignal342.31.726
headacheSignal212.01.310
pruritus121.91.14
diarrhoea171.61.03
pain141.40.81
nausea161.20.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.